The News

Addex Presents ADX10059 GERD Data at Conference

06/11/2007

Paris, France – Allosteric modulation company Addex Pharmaceuticals (SWX:ADXN, Geneva, Switzerland) presented new data from its Phase IIa trial of ADX10059 to treat gastroesophageal reflux disease (GERD) today at the United European Gastroenterology Week (www.uegw.org) conference in Paris, France. GERD is a common disorder, affecting about 15% of the population. New data released today for the first time show that ADX10059 controlled stomach acid reflux during the critical period following meals, when GERD can be most troublesome. Top-line data, first released in April, showed that the product controlled acid reflux over a 24 hour period.
“Despite the benefits of the leading prescription therapies for GERD, stomach acid reflux occurring after meals and at night remains a significant area of unmet need for GERD sufferers. The data from this early study with ADX10059 are encouraging as the compound appears to have meaningful effects at these times,” said Charlotte Keywood, chief medical officer at Addex. “Some studies indicate that about 50% of GERD patients are not adequately controlled by marketed therapies.”

2007

Click here for the site of Sofinnova Ventures, our sister firm in San Francisco http://www.sofinnova.com